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Results: Mean(standard deviation) V95 of the PTV of all plans was 
98.6(4.3), and 94.7(5.8) in the recomputed plans on the localization 
CT (p=0.007). V95 for the GTV was 99.6(4.1) and 99.0(4.7) on the 
localization and the planning CT, respectively; this difference was not 
significant (p=0.0549). V98 for the GTV was 82.3(10.9) and 83.5(13.6) 
on the localization and the planning CT, respectively; this difference 
was again not significant (p=0.1483). 
Conclusions: The coverage of the PTV (5 mm margin) was significantly 
lower in the recomputation on the localization CT, whereas V95 and 
V98 of the GTV remained unchanged in this group of patients. The 
clinical relevance of these changes remains to be elucidated. Jet 
ventilation appears to be a feasible technique for irradiation of small 
peripheral tumors with proton therapy. The study of new planning 
strategies and margin concepts is warranted. 
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Purpose/Objective: Proton therapy is more sensitive (less robust) to 
geometrical uncertainties than photon therapy. Different methods 
have been proposed to increase proton plan robustness. These 
methods include robust CTV-based planning as an alternative to 
conventional PTV-margin based planning. Thus, different changes will 
be combined in the intended improvement for proton therapy. The 
purpose of this study was to test the robustness of scanned-beam 
intensity-modulated proton therapy (IMPT) to setup errors and 
geometrical changes compared to IMRT for head and neck cancer if 
conventional PTV-margin based planning would be used. 
Materials and Methods: In 10 patients with laryngeal or pharyngeal 
cancer, a planning-CT (CT0) and a repeat-CT scan (CT1) during the 
course of radiotherapy were made (median interval 25 days). Five 
patients had relatively small shape changes and 5 patients had 
relatively large shape changes. Target volumes were delineated on 
CT0, including a uniform 5 mm margin from CTV to PTV. IMPT and 
IMRT plans were made with optimal sparing of the parotid glands and 
swallowing organs at risk (SWOARs). Structures were propagated from 
CT0 to CT1 after deformable image registration. Subsequently, rigid 
registration and plan reconstruction on CT1 was performed simulating: 
1) no correction for setup errors; 2) off-line correction; and 3) on-line 
correction. 
Results: Planning objectives (including strict criteria for target 
coverage and dose in critical structures such as the spinal cord) were 
fulfilled in all plans on CT0. Coverage of the CTV was adequate with 
IMRT on CT1 regardless of the correction method, and with IMPT after 
on-line position correction. In two patients, the tumour-CTV shrunk 
with 25% and 28%, respectively. With IMPT this resulted in a spinal 
cord dose that exceeded the tolerance dose (it ranged from 55.0 Gy to 
62.5 Gy in these two cases with the different position correction 
methods). The mean parotid gland dose was lowest with IMPT on both 
CT0 and CT1, but increased on CT1 with IMPT more than with IMRT (see 
table). The mean dose in the SWOARs on CT0 was lowest with IMPT. 
On CT1, the mean dose in the superior pharyngeal constructor muscle 
was lowest with IMPT and the mean dose in the supraglottic larynx 
was lowest with IMRT. The influence of the setup correction method 
on the mean parotid gland and SWOAR dose on CT1 was relatively 
small. Dose changes in OARs were mainly caused by changes in patient 
geometry during the interval between CT0 and CT1. 
 
 
Conclusions: With conventional PTV-margin based planning, IMPT 
would be less robust to geometrical changes than IMRT, resulting in 
reduced gains with regard to the mean dose delivered to OARs on CT1. 
Adaptive CTV-based treatment strategies are expected to fully exploit 
the benefits of IMPT, especially for patients with large geometrical 
changes. This study defines a reference to quantify the benefit of 
these proton strategies.  
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Purpose/Objective: 1)To evaluate the dosimetric effects of anatomy 
changes in patients affected by malignant pleural mesothelioma 
(MPM) on intensity modulated proton therapy (IMPT) plans and 2) to 
propose an approach to mitigate this effect. 
Materials and Methods: The study was based on the planning CT and 
either 3 or 4 verification CT scans acquired during the course of the 
treatment of five patients treated with trimodality approach (surgery 
+ chemo + radiationtherapy). CT scans were registered with automatic 
rigid registration on bony anatomy. Structures’ contours were copied 
on the verification CTs and manually adjusted by a radiation 
oncologist. Changes in the volume of air pockets within the CTV over 
the treatment course were quantified. 
For each patient, a 2-fields IMPT plan was generated on the planning 
CT in our TPS (Elekta XiO 4.64) and then re-calculated on the 
verification CTs. Several dosimetric indexes for PTV and OARs were 
used to quantify the differences between planned and recalculated 
dose distributions (see table). 
As a term of comparison, for one patient an IMRT plan was designed 
on the planning CT and then recalculated on the verification CTs. 
The effect of replanning early in the treatment cycle was evaluated 
by replanning on the first control CT (taken after about one week of 
treatment) and then recalculating on the remaining control CTs. 
Results: The CT data showed a systematic reduction of the air volume 
in the CTV over the treatment course: the mean reduction between 
planning CT and last control CT was 80±13% (range: 63-100%). The 
dosimetric impact on the planned dose distributions is summarized in 
table. A decrease of V98 in the CTV up to 17.2% was observed, along 
with an absolute +24% in V107. Dramatic discrepancies were not 
observed for OARs: the typical increase in mean dose for liver and 
ipsilateral kidney was 2Gy and 3Gy, respectively. However relative 
differences up to 40% were found in V40 for oesophagus. The IMRT 
plan provided similar results as IMPT concerning target coverage, 
while for OARs it is more robust. However even after the last 
recalculation IMPT is still better. When IMPT treatments were re-
planned on the first verification CT and then recalculated on the 
remaining verification CTs, smaller differences were found (see 
figure), especially concerning the target coverage (on average V98 
decreased only by 4.7%). For both the liver and ipsilateral kidney the 
mean dose increase was less than 1 Gy. A 4D-CT scan was acquired for 
one patients to assess intrafraction organ motion. Results showed no 
impact. 
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Conclusions: A systematic reduction of air pockets within CTV occurs 
over treatment course. While these anatomical changes don’t affect 
so much the dosimetric outcome in term of OAR irradiation, a not 
negligible degradation of target coverage and dose homogeneity is 
pointed-out. In some cases this degradation couldn’t be clinically 
tolerable. If re-planning is performed on the first control CT the 
stability of dose distributions over the remaining treatment time 
improves.  
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Purpose/Objective: Proton therapy has the potential to deliver a 
superior distribution of radiation dose to the patient compared with 
photon therapy. On the other hand, proton treatments are more 
sensitive to setup variations and anatomical changes. In particular, a 
site where proton therapy could be highly beneficial is lung cancer. 
However, the anatomical changes in lung cancer provide a big 
challenge to deliver the planned dose. As part of the development of 
probabilistic planning systems, where knowledge about geometric 
uncertainties is taken into account during plan optimization, we are 
studying the effect of observed anatomical changes in lung cancer 
patients on scanned beam proton treatments. 
Materials and Methods: We selected three lung cancer patients with 
tumors close to the mediastinum that might be eligible for SBRT with 
protons, while they cannot be delivered with photons due to dose 
limiting constraints. For each patient we had the planning CT and five 
CBCT scans available. We used the research Pinnacle³ Intensity 
Modulated Proton Therapy (IMPT)/Spot Scanning treatment planning 
system (TPS)version 9.100 to create a proton plan for each patient 
using the original planning CT scan. These proton plans were kept very 
simple, consisting of two beams and optimized using the same 
objectives as the photon treatment plan. For every fraction, a CBCT 
was made just before the treatment. These scans represent the 
anatomy of the patient at that particular treatment day. We did not 
consider respiration motion, but used motion compensated CBCT scans 
to describe the 'baseline' anatomical changes. The CBCT scans cannot 
be directly used in the TPS to recalculate the dose as Hounsfield unit 
are not calibrated. Instead,the planning CT scan was deformed to 
every CBCT with in-house software, and dose was next recalculated 
using the original plan in Pinnacle³. The dose differences between the 
planned and delivered proton dose was evaluated 
Results:  
 
PTVmaxdose 
A(PTVmean = 
66.495Gy) 
B (PTVmean = 
66.685Gy) 
C (PTVmean = 
66.685Gy) 
difference 
(Gy) 
relative 
diff (%) 
difference 
(Gy) 
relative 
diff (%) 
difference 
(Gy) 
relative 
diff (%)  
scan1  23.40 -35.19 56.66 -84.91 29.85 -44.77 
scan2 23.84 -35.75 25.65 -38.46 46.50 -69.74 
scan3 26.56 -39.84 25.48 -38.21 44.63 -66.94 
scan4 23.46 -35.28 35.84 -53.75 36.81 -55.21 
scan5 22.35 -33.61 25.71 -38.55 28.26 -42.39 
mean 23.92 -35.93 33.87 -50.79 37.21 -55.81 
standard 
deviation 2.58 2.33 13.49 20.23 8.30 12.45 
 
(table caption: table 1 The maximum dose difference between the 
planningCT and the CBCT scans of the three patients inthe PTV) 
The results in table 1 show a remarkable underdosages in the planning 
treatment volume (PTV) coverage from 36% to 56%. 
Conclusions: Patient anatomy changes occuring during typical lung 
treatments, lead to significant under and overdosage, e.g. the PTV 
underdosages shown in this study. Based on this study, we can 
conclude that classical planning strategies applied for proton therapy 
are unsafe in the lung, and that more advanced planning strategies 
including knowledge of geometrical uncertainties need to be 
developed. 
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Purpose/Objective: To determine and assess the dosimetric 
difference between three emerging treatment modalities, which are 
intensity modulated proton therapy (IMPT), intensity modulated 
carbon ion beam therapy (IMIT) and rotational IMRT (VMAT) for two 
tumour sites where selective boosting of the tumour is applied.  
Materials and Methods: The planning study was retrospectively 
performed on each 10 patients with locally advanced head-and-neck 
(H&N) cancer and high-risk prostate cancer (PC). For each patient a 
VMAT plan was generated for the PTVinitial that included LN regions, 
delivering 50 GyE for H&N and 50.4 GyE for PC patients. Furthermore, 
3 separate boost plans (VMAT, IMPT and IMIT) were created to boost 
the PTVboost up to 70 GyE and 78 GyE for H&N and PC cases, 
respectively. Doses to the primary OARs i.e brainstem, myelon, larynx 
and parotid glands were assessed for H&N cases. Additionally, various 
OARs whose sparing can be associated with improved quality of life 
after treatment were delineated. For PC cases doses to bladder, 
rectum as well as femoral heads were analyzed. In order to sum up 
the total doses, dose matrices of the initial VMAT plans and the 
respective boost plans were mapped together. 
Results: H&N cases: The targets goals were easily met, with higher 
median dose found for VMAT+VMAT compared to VMAT+IMPT and 
VMAT+IMIT (58.2 (4.9) GyE, 53.8 (3.9) GyE, 53.4 (1.3) GyE, 
respectively). All the primary OARs were spared the least by the 
VMAT+VMAT method. Mean doses for VMAT+IMPT and VMAT+IMIT was 
approximately 3 GyE lower for contralateral parotis and 1.5 GyE lower 
for larynx comparing to VMAT+VMAT results. Similarly, D2GyE was on 
average 2 GyE lower for myleon and 2.6 GyE lower for brainstem. 
Moreover, no significant difference was detected between VMAT+IMPT 
and VMAT+IMIT. Considering additional OARs a big improvement was 
found for the VMAT+IMIT method especially in sparing the ipsilateral 
cochlea, middle ear, masticator space as well as the base of tongue 
and soft palate. 
PC cases: In terms of target coverage all 3 modalities reached the 
prescribed goals, with slightly higher average median dose to PTVinital 
for the VMAT+VMAT method, 52.3 (3.2) GyE compared to VMAT+IMPT 
and VMAT+IMIT (51.1 (1.7) GyE and 51.2 (1.4) GyE respectively). 
Similarly, V95% was found to be higher for PTVinitial (VMAT+VMAT = 99.1% 
